Stockhead on MSN21m
Health Check: Opthea’s solvency in question after monumental phase III eye disease trial failureOne of two of Opthea's phase III trials for a common eye disease has failed to meet its primary endpoints, ... Read More The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback